B
Bart Barlogie
Researcher at Mount Sinai Hospital
Publications - 47
Citations - 6242
Bart Barlogie is an academic researcher from Mount Sinai Hospital. The author has contributed to research in topics: Multiple myeloma & Gene expression profiling. The author has an hindex of 18, co-authored 47 publications receiving 5939 citations. Previous affiliations of Bart Barlogie include Millennium Pharmaceuticals & University of Arkansas for Medical Sciences.
Papers
More filters
Journal ArticleDOI
A phase 2 study of bortezomib in relapsed, refractory myeloma.
Paul G. Richardson,Bart Barlogie,James R. Berenson,Seema Singhal,Sundar Jagannath,D. Irwin,S. Vincent Rajkumar,Gordan Srkalovic,Melissa Alsina,Raymond Alexanian,David S. Siegel,Robert Z. Orlowski,David J. Kuter,Steven Limentani,Stephanie J. Lee,Teru Hideshima,Dixie Lee Esseltine,Michael Kauffman,Julian Adams,David P. Schenkein,Kenneth C. Anderson +20 more
TL;DR: Bortezomib, a member of a new class of anticancer drugs, is active in patients with relapsed multiple myeloma that is refractory to conventional chemotherapy.
Journal ArticleDOI
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
Sundar Jagannath,Bart Barlogie,James R. Berenson,David S. Siegel,D. Irwin,Paul G. Richardson,Ruben Niesvizky,Raymond Alexanian,Steven Limentani,Melissa Alsina,Julian Adams,Michael Kauffman,Dixie Lee Esseltine,David P. Schenkein,Kenneth C. Anderson +14 more
TL;DR: Bortezomib alone or in combination with dexamethasone demonstrated therapeutic activity in patients with multiple myeloma who relapsed after frontline therapy.
Journal ArticleDOI
CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
Eric D. Hsi,Roxanne Steinle,Balaji Balasa,Susann Szmania,Aparna Draksharapu,Benny P. Shum,Mahrukh Huseni,David M. W. Powers,Amulya Nanisetti,Yin Zhang,Audie Rice,Anne van Abbema,Melanie Wong,Gao Liu,Fenghuang Zhan,Myles B.C. Dillon,Shihao Chen,Susan Rhodes,Franklin Fuh,Naoya Tsurushita,Shankar Kumar,Vladimir Vexler,John D. Shaughnessy,Bart Barlogie,Frits van Rhee,Mohamad A. Hussein,Daniel E. H. Afar,Marna Williams +27 more
TL;DR: It is suggested that HuLuc63 eliminates myeloma cells, at least in part, via NK-mediated ADCC and shows the therapeutic potential of targeting CS1 with Hu Luc63 for the treatment of multipleMyeloma.
Journal ArticleDOI
Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321
Bart Barlogie,Robert A. Kyle,Kenneth C. Anderson,Philip R. Greipp,Hillard M. Lazarus,David D. Hurd,Jason McCoy,Dennis F. Moore,Shaker R. Dakhil,Keith S. Lanier,Robert A. Chapman,Jeana N. Cromer,Sydney E. Salmon,Brian G.M. Durie,John Crowley +14 more
TL;DR: The HDT and SDT regimens used in S9321 yielded comparable response rates and PFS and OS durations, and IFN maintenance therapy did not benefit patients who achieved > or = 75% tumor reduction on either arm.
Journal ArticleDOI
Magnetic Resonance Imaging in Multiple Myeloma: Diagnostic and Clinical Implications
Ronald C. Walker,Bart Barlogie,Jeffrey Haessler,Guido J Tricot,Elias Anaissie,John D. Shaughnessy,Joshua Epstein,Rudy Van Hemert,Eren Erdem,Antje Hoering,John Crowley,Ernest Ferris,Klaus Hollmig,Frits van Rhee,Maurizio Zangari,Mauricio Pineda-Roman,Abid Mohiuddin,Shmuel Yaccoby,Jeffrey Sawyer,Edgardo J. Angtuaco +19 more
TL;DR: MRI is a more powerful tool for detection of FLs than is MBS and is recommended that, in addition to MBS, MRI be used routinely for staging, prognosis, and response assessment in myeloma.